Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the disease control rate and time to progression of the sequential
combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil
hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102
oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)